Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heparin pharmaceutical composition, nasal spray and preparation method and application of heparin pharmaceutical composition or nasal spray

A composition and heparin technology, applied in the field of medicine, can solve problems such as poor, single prevention effect of new coronavirus infection, and achieve the effect of enhancing protection ability

Active Publication Date: 2021-03-26
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to overcome the defects that the method for preventing novel coronavirus infection in the prior art is relatively single and the prevention effect is not good, and provides a heparin pharmaceutical composition, nasal spray and its preparation method and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heparin pharmaceutical composition, nasal spray and preparation method and application of heparin pharmaceutical composition or nasal spray
  • Heparin pharmaceutical composition, nasal spray and preparation method and application of heparin pharmaceutical composition or nasal spray

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. Materials

[0039] Unfractionated heparin sodium was purchased from Ron (185 USP units / mg), Arbidol (purity 98%, purchased from Aladdin)

[0040] 293T cells overexpressing ACE2 and the pseudovirus of SARS-Cov-2 S protein were purchased from Changsha Junyi Huaxiang Biotechnology Co., Ltd.

[0041] In this embodiment, the concentration gradient of the combined drug is set as follows:

[0042] Unfractionated heparin sodium: 6μg / L, 3μg / L, 1.5μg / L;

[0043] Arbidol: 4μM / L, 2μM / L, 1μM / L

[0044] In this embodiment, the formulas with the concentrations shown in Table 1 are configured altogether.

[0045] Table 1

[0046]

[0047] 2. Experimental method

[0048] Mix 200 TCID50 of a pseudovirus expressing SARS-CoV-2 S protein with a series of drug combinations of different concentrations, with a total volume of 100 μl; add to a 96-well cell culture plate, incubate at 37°C for 1 hour, add 100 μl containing 20,000 overexpressed 293T cells with ACE2; negative control gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a heparin pharmaceutical composition, a nasal spray and a preparation method and application of the heparin pharmaceutical composition or nasal spray. The heparin pharmaceutical composition comprises heparin sodium and arbidol. According to the heparin pharmaceutical composition disclosed by the invention, it is the first time that the heparin sodium and the arbidol are used in combination, and the virus inhibition efficiency of common heparin sodium combined with the arbidol of 1[mu]M / L or more is remarkably higher than that of the single common heparin sodium or single arbidol group (p<0.05).

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a heparin pharmaceutical composition, a nasal spray and a preparation method and application thereof. Background technique [0002] In December 2019, the outbreak of novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) developed rapidly and has now spread globally, causing huge economic losses worldwide. COVID-19 is highly contagious, with atypical early symptoms, and currently there is no specific drug for treatment. At present, it is believed that the transmission route of the virus is respiratory droplets and close contact transmission. There is a possibility of aerosol transmission when exposed to high-concentration aerosols for a long time in a relatively closed environment. The source of infection is mainly patients infected with the new coronavirus. The "Guidelines for the Use of Pneumonia Masks to Prevent Novel Co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/727A61K31/704A61K31/4045A61K9/00A61P31/14
CPCA61K9/0043A61K31/4045A61K31/704A61K31/727A61K47/02A61P31/14A61K2300/00
Inventor 张伟江军仪
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com